论文部分内容阅读
目的:探究培美曲赛单药治疗晚期非小细胞肺癌的疗效与安全性。方法:选取我院2011年3月~2014年10月收治的晚期非小细胞肺癌患者50例作为本次的研究对象,随机分为观察组和常规组,每组患者各25例。观察组采用培美曲赛单药治疗,常规组采用多西他赛联合柏顺化疗,比较两组患者的化疗效果与并发症发生率。结果:比较两组患者的完全缓解率与总缓解率元明显差异(P>0.05);且观察组并发症的发生率明显低于常规组,比较差异显著(P<0.05)。结论:对晚期非小细胞肺癌患者采用培美曲赛单药化疗的临床效果显著,并发症发生率低,值得进一步推广并应用。
Objective: To investigate the efficacy and safety of pemetrexed monotherapy in the treatment of advanced non-small cell lung cancer. Methods: Fifty patients with advanced non-small cell lung cancer admitted to our hospital from March 2011 to October 2014 were selected as the study subjects and randomly divided into observation group and conventional group, with 25 patients in each group. The observation group was treated with pemetrexed monotherapy, and the docetaxel combined with cisplatin in the conventional group was used to compare the chemotherapy effect and complication rate between the two groups. Results: The complete remission rate and total remission rate were significantly different between the two groups (P> 0.05). The incidence of complications in the observation group was significantly lower than that in the conventional group (P <0.05). Conclusion: The clinical effect of pemetrexed monotherapy in patients with advanced non-small cell lung cancer is significant, and the complication rate is low. It is worth further promotion and application.